Prevalence of neuroleptic-induced movement disorders: an 8-year follow-up study in chronic schizophrenia inpatients

Nordic Journal of Psychiatry

Volumn 70, Issue 7, 2016, Pages 498-502

  Parksepp, Madis ^a   Ljubajev, Ülle ^a   Täht, Karin ^a   Janno, Sven ^a  

^a UNIVERSITY OF TARTU   (Estonia)

Author keywords

Akathisia; Antipsychotic treatment; Neuroleptic induced parkinsonism; Schizophrenia; Tardive dyskinesia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; HALOPERIDOL; MELPERONE; NEUROLEPTIC AGENT; PERPHENAZINE; RISPERIDONE; SERTINDOLE; ZUCLOPENTHIXOL;

ADULT; AGED; AKATHISIA; ARTICLE; DISEASE SEVERITY; DSM-IV; FEMALE; FOLLOW UP; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; PARKINSONISM; PREVALENCE; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT DURATION; DYSKINESIA, DRUG-INDUCED; ESTONIA; MIDDLE AGED;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; ESTONIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PREVALENCE; SCHIZOPHRENIA;

EID: 84964374832     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.3109/08039488.2016.1164245     Document Type: Article

References (22)

1. Estonian State Agency of Medicines:Statistics of Antipsychotic Drugs Usage in Estonia Compared to other EU countries. Available at:http://www.ravimiamet.ee/vvfiles/0/Eesti ravimistatistika 2006-2009.pdf.
2. S.J.Edwards, C.J.Smith Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder:A mixed treatment comparison of randomized controlled trials. Clin Ther 2009;31:1345–59.
3. S.Janno, M.Holi, K.Tuisku, K.Wahlbeck Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry 2004;161:160–3.
4. Cunningham Owens DG. Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs. Cambridge:Cambridge University Press; 1999.
5. R.Kumar, P.Sachdev Akathisia and second-generation antipsychotic drugs. Curr Opin Psychiatry 2009;22:293–99.
6. J.Modestin, M.Wehrli, P.Stephan, P.Agarwalla Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment. Schizophr Res 2008;100:97–107.
7. D.Tarsy, R.Baldessarini, F.Tarazi Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002;16:23–4.
8. S.W.Woods, H.Morgenstern, J.R.Saksa, B.C.Walsh, M.C.Sullivan, R.Money,. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications:A prospective cohort study. J Clin Psychiatry 2010;71:463–74.
9. C.Correll, S.Leucht, J.Kane Lower risk for tardive dyskinesia associated with second-generation antipsychotics:A systematic review of 1-year studies. Am J Psychiatry 2004;161:414–25.
10. J.Geddes, N.Freemantle, P.Harrison, P.Bebbington, for the National Schizophrenia Guideline Development Group. Atypical antipsychotics in the treatment of schizophrenia:systematic overview and meta-regression analysis. BMJ 2000;321:1371–6.
11. J.A.Lieberman, T.S.Stroup, J.P.McEvoy, M.S.Swartz, R.A.Rosenheck, D.O.Perkins,. Clinical antipsychotic trials of intervention effectiveness (CATIE) investigators:Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209–23.
12. S.M.Stahl Prescriber's Guide. 3rd ed. Cambridge:Cambridge University Press, 2009.
13. American Psychiatric Association:Practice Guideline for Treatment of Patients With Schizophrenia. Second Edition 2004 Available at:http://www.psychiatryonline.com/pracGuide/loadGuidelinePdf.aspx?file=Schizophrenia2e.
14. Eesti Psühhiaatrite Selts Eesti skisofreenia ravijuhis [Estonian Association of Psychiatrists Guideline for Schizophrenia]; 2000. Available at:http://www.kliinikum.ee/psyhhiaatriakliinik/lisad/ravi/ps-ravi/SCH/skisofreenia_ravijuhis.htm.
15. T.R.Barnes A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672–6.
16. G.M.Simpson, J.W.S.Angus A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;213:11–19.
17. M.Munetz, S.Benjamin How to examine patients using the abnormal involuntary movement scale. Hosp Community Psychiatry 1988;39:1172–7.
18. D.M.Gardner, A.L.Murphy, H.O'Donnell, F.Centorrino, R.J.Baldessarini International consensus study of antipsychotic dosing. Am J Psychiatry 2010;167:686–93.
19. S.Bazire Psychotropic Drug Directory. Salisbury:Fivepin; 2003.
20. WHO Collaborating Centre for Drug Statistics Methodology Available at:http://www.whocc.no/atc_ddd_index/?code=N05A. [cited 2015 Apr 12].
21. D.D.Miller, J.P.McEvoy, S.M.Davis, S.N.Caroff, B.L.Saltz, M.H.Chakos,. Clinical correlates of tardive dyskinesia in schizophrenia:Baseline data from the CATIE schizophrenia trial. Schizophr Res 2005;80:33–43.
22. A.Chatterjee, M.Chakos, A.Koreen, S.Geisler, B.Sheitman, M.Woerner,. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in nevermedicated schizophrenic patients. Am J Psychiatry 1995;152:1724–9.